Advertisement
Review

p27 as a Transcriptional Regulator: New Roles in Development and Cancer

Seyedeh Fatemeh Razavipour, Kuzhuvelil B. Harikumar and Joyce M. Slingerland
DOI: 10.1158/0008-5472.CAN-19-3663 Published September 2020

Abstract

p27 binds and inhibits cyclin-CDK to arrest the cell cycle. p27 also regulates other processes including cell migration and development independent of its cyclin-dependent kinase (CDK) inhibitory action. p27 is an atypical tumor suppressor–deletion or mutational inactivation of the gene encoding p27, CDKN1B, is rare in human cancers. p27 is rarely fully lost in cancers because it can play both tumor suppressive and oncogenic roles. Until recently, the paradigm was that oncogenic deregulation results from either loss of growth restraint due to excess p27 proteolysis or from an oncogenic gain of function through PI3K-mediated C-terminal p27 phosphorylation, which disrupts the cytoskeleton to increase cell motility and metastasis. In cancers, C-terminal phosphorylation alters p27 protein–protein interactions and shifts p27 from CDK inhibitor to oncogene. Recent data indicate p27 regulates transcription and acts as a transcriptional coregulator of cJun. C-terminal p27 phosphorylation increases p27-cJun recruitment to and action on target genes to drive oncogenic pathways and repress differentiation programs. This review focuses on noncanonical, CDK-independent functions of p27 in migration, invasion, development, and gene expression, with emphasis on how transcriptional regulation by p27 illuminates its actions in cancer. A better understanding of how p27-associated transcriptional complexes are regulated might identify new therapeutic targets at the interface between differentiation and growth control.

p27 Is a Ubiquitously Expressed Cell-Cycle Inhibitor

The CDKN1B gene encodes p27, a cyclin-dependent kinase inhibitor (CDKi) of the kinase inhibitory protein (Kip) family. CDKis mediate cell-cycle inhibition. p27 is ubiquitously expressed and integrates mitogenic and growth inhibitory signals to govern normal cell-cycle progression (1). p27 can inhibit the catalytic activity of cyclin D-, E-, A-, and B-CDK complexes (2) by interacting with both cyclin and CDK subunits via its N-terminal domain, which is conserved among Kip family members (p21, p27, and p57; refs. 1, 3).

Antiproliferative and differentiation signals increase p27 to mediate cell-cycle arrest (2, 4–7). In normal cells, p27 levels are tightly regulated across the cell cycle. An increase in p27 by 2- to 3-fold is sufficient to fully inhibit G1–S-phase cyclin-CDKs (8). In G0-phase and early G1-phase, p27 protein translation and stability are maximal (9–13) and it inhibits cyclin E-CDK2 (2, 14). A progressive decline in p27 is required to relieve the inhibition of cyclin E- and cyclin A–bound CDK2 and enable transcription of genes required for G1- to S-phase progression (1). Transient C-terminal p27 phosphorylation by PI3K/AKT in mid-G1-phase facilitates assembly and nuclear import of D-type cyclin-CDKs (15), permitting their activation (3, 15, 16). p27 proteolysis increases during G1-phase progression via a number of mechanisms. Phosphorylation at p27T187 by cyclin E or cyclin A–bound CDK2 triggers p27 turnover by promoting its polyubiquitination and degradation by the SCFSkp2 ubiquitin ligase complex [S-phase kinase associated protein 1 (SKP1)/Cullin/F-Box protein: SKP2; refs. 17–19]. But how does the target kinase, cyclin E–bound CDK2, phosphorylate its own inhibitor? In G1-phase, Src family kinases phosphorylate p27 in its CDK inhibitory domain at Y74, Y88, and Y89 (20, 21). Phosphorylation of p27Y88 within the 310-helix that binds the ATP pocket in CDK2, leads to ejection of p27 from the catalytic cleft of CDK2, permitting kinase activation (20, 21). CDK2 can then phosphorylate p27 at T187 to trigger p27 proteolysis at the G1–S-phase transition. p27 is also degraded independently of T187 phosphorylation (see Fig. 1A). In early G1-phase, p27 phosphorylation at S10 (22, 23) leads to its export to the cytoplasm. Cytoplasmic p27 can be ubiquitylated by the ubiquitin ligase Kip1 ubiquitylation-promoting complex to mediate its degradation (24).

Figure 1.
Figure 1.

A, Schematic of p27 domains and phosphorylation sites. Kinases that phosphorylate p27 are indicated. B, Transcription factors that interact with p27 and p27 target genes validated by ChIP-PCR are shown (the superscripts on p27 target genes indicate the relevant references).

p27 Acquires Novel Functions through C-terminal Phosphorylation by PI3K Effector Kinases

C-terminal p27 phosphorylation regulates p27 function. PI3K promotes growth, survival, and motility (25–27) of both normal and cancer cells (28). PI3K activates downstream kinases, including AKT, SGK, 70 kDa S6 kinase (p70S6K), and 90 kDa ribosomal S6 kinase (p90RSK; refs. 26, 27, 29). These in turn phosphorylate p27 at T157 (30–32) to delay p27 nuclear import (30, 33) and at T198 (34, 35) to stabilize p27pT157pT198 (hereafter p27pTpT; refs. 36, 37).

p27 plays cell-cycle–independent actions to regulate cell motility (38, 39). Early work showed transduction of p27–TAT fusion protein into HepG2 cells increased cytoplasmic p27 and promoted cell migration (40). When p27null mouse embryo fibroblasts (MEF) were found to have impaired cell motility, this led to the discovery that p27 binds and inhibits RhoA-ROCK, leading to destabilization of the actin cytoskeleton and increased cell motility (38, 39). This p27 action is independent of cyclin/CDK binding, because the motility of p27null MEFs is restored equally by either WTp27 or by a p27CK− mutant that cannot bind cyclins and CDKs (38, 39). p27 phosphorylation at T198 promotes its interaction with RhoA and RhoA-ROCK1 inhibition (41, 42) to drive cell motility. While the precise role of p27-mediated cytoskeletal changes in normal cells are not fully known, these might serve to remodel cell shape in G1-phase to permit later changes during mitosis and cytokinesis.

p27 is also expressed in cortical neurons and neuronal progenitors and regulates interneuron migration. p27 plays roles in neuronal development and axonal transport via several mechanisms. Defects in the kinetics of nucleokinesis and tangential neuronal migration were observed in p27null mice (43), potentially through loss of p27/RhoA binding. p27 also promotes neuronal microtubule polymerization during neurite outgrowth (44, 45). p27 also appears to bind and stabilize alpha tubulin acetyl transferase 1 to promote microtubule acetylation and stability to regulate axonal transport (46). In addition to its effects on cell motility, p27 plays a number of roles that are independent of CDK inhibition to regulate autophagy, apoptosis, stem/progenitor fate, and cytokinesis (37, 47, 48).

Loss of CDK Inhibition by p27 in Cancers

p27 loss through decreased synthesis and excess proteolysis

Oncogenic activation of the SRC, MAPK, and PI3K signaling pathways deregulate p27 in cancers (1, 49). While high nuclear p27 levels restrain normal cell proliferation (50), p27 is nearly always deregulated in cancers (20). Human cancers often show reduced nuclear p27 (50–53) and this is associated with poor patient prognosis (1). This occurs predominantly through activation of SCFSKP2-dependent p27 proteolysis (17, 24, 36). Activation of ABL, LYN, LCK, and FYN in lymphoma and other hematopoietic malignancies also promotes p27 proteolysis (54). In addition, SRC activation (20) and ERBB2 amplification (55) are associated with reduced p27 in human breast cancer. p27 loss in human cancers can also result from oncogenic overexpression of miRNAs that impair p27 translation (reviewed in ref. 12). p27 is a key target of the miR-221/222 in multiple malignancies including glioblastoma (56, 57), triple-negative breast (58), hepatocellular (59), and papillary thyroid carcinoma (60). Other miRNAs also target p27 including miR-196a in cervical cancer (61), miR-24 in prostate cancer (62), miR-152-3p in chronic myelogenous leukemia (63), miR-148a in myeloma (64), and miR-199-a in osteosarcoma (65). p27 translation can also be regulated by long noncoding RNAs via ribonucleoprotein complexes (66), but the relevance of this mechanism to p27 loss in cancers is not known.

Constitutive C-terminal phosphorylation via oncogenic PI3K pathway activation

The PI3K pathway is oncogenically activated in a majority of human cancers (28). PI3K/AKT-activated cancers have constitutively C-terminally phosphorylated p27 that accumulates aberrantly in both the cytoplasm and nucleus and binds novel proteins to drive tumor progression (30–32). We and others showed AKT can phosphorylate p27 (30–32), impair nuclear import, and a highly stable p27 accumulates in the cytoplasm in PI3K-activated human breast cancers and is associated with poor patient outcome (30, 67). Cytoplasmic p27 was also observed in cancer models with oncogenic activation of Ras, PKC, or Pim kinases (68–71). Notably, PI3K inhibition restored nuclear localization of p27 in a K-Ras–activated lung cancer model (72). Cytoplasmic p27 is associated with increased metastasis and poor survival in a number of cancer types (1, 67). Indeed, overexpression of p27CK− coupled to a triple-nuclear export signal increased melanoma metastasis in vivo, suggesting p27 might have oncogenic actions independent of CDK inhibition (73). Activation of AKT/PI3K and accumulation of p27pTpT has been shown to increase tumor metastasis in several cancer models including breast and urothelial cancers (74–76). While the oncogenic action of C-terminally phosphorylated p27 was initially thought to result from cytoplasmic mislocalization (30), increased cyclin D-CDK4 assembly (3, 15) or RhoA/ROCK1 inhibition and cytoskeletal changes causing greater tumor invasion (38, 39), recent work has identified additional p27pTpT-interacting partners and novel oncogenic actions (see Figs. 1B and 2).

Figure 2.
Figure 2.

Cartoon depicts signaling pathways linked to transcriptional regulation by p27 and interacting coregulators. ECM, extracellular matrix; HGF, hepatocyte growth factor; TF, transcription factor.

Increasing data indicate that p27pTpT acts as a transcriptional regulator to drive metastasis (75, 76). When p27pTpT accumulates due to PI3K activation, it associates with transcription factors STAT3 (75) and cJun (76) to drive transcription programs of epithelial–mesenchymal transition (EMT) and metastasis (reviewed below). cJun is a known regulator of tissue morphogenesis and multi-organ tissue differentiation (77). The finding that p27-cJun–driven genes govern developmental processes may illuminate work from 20 years ago that implicated p27 as a regulator of tissue differentiation in normal development. Before actions of p27 as a transcriptional regulator are discussed, we will briefly review lessons from mouse models on p27 action in differentiation and development.

p27 Plays Cyclin-CDK–Independent Roles in Development

p27−/− mice have a phenotype of gigantism due to multi-organ hyperplasia, and maldevelopment of retina, central nervous system, pituitary, and ovary (78–80). This has been attributed to failure to arrest the cell cycle during differentiation (78–80). Mice lacking p27 uniformly exhibit tumor formation in the pituitary (78–80); and haploinsufficient animals are carcinogen sensitive (81). Spleen and thymus enlargement in p27-null mice are associated with an expansion of committed hematopoietic progenitors of granulocytic and erythroid lineages, without increase in pluripotent hematopoietic stem cells (80, 82), and spontaneous T-cell lymphoma emerge in 6%. p27−/− mice also show maldevelopment of neural structures, retina, and pituitary, and pituitary adenoma cause premature death of nearly all mice at approximately 10 months (78–80). Notably, knockin of a cell-cycle defective p27 mutant that cannot bind cyclin or CDKs (p27CK−) failed to correct the large animal size, providing additional support for the notion that the CDK inhibitory function of p27 somehow coordinates stem/progenitor expansion in various tissues with cell-cycle arrest at differentiation (83). Furthermore, some developmental defects of the p27-null phenotype were corrected in the p27CK− knockin, indicating that some developmental actions of p27 are CDK independent (83). The p27CK− knockin mice showed stem cell expansion, hyperplasia, and neoplasia in the lung, not seen in p27−/− and a greater frequency of hyperplasia of pituitary, adrenal, spleen, and thymus and more T-cell lymphomas (20%; ref. 83). The widespread differentiation defects and increased progenitor self-renewal in multiple tissues, suggested p27CK− expression without cell-cycle restraint might misregulate progenitor/stem cells. The developmental phenotypes of p27-null and p27CK− knockin mice were initially interpreted in light of p27′s known CDK inhibitor action. However, CDK2 loss did not compensate the p27null phenotype in the double knockout (84, 85) and subsequent studies soon showed further evidence for CDK-independent p27 actions in differentiation.

The p27 homologue in Xenopus, Xic1, is required for normal muscle (86, 87) and neuronal differentiation (88–90). This prodifferentiation function is cell-cycle independent (86, 87), because Xic1 is required prior to growth arrest during differentiation and because a mutant xic1, which cannot bind cyclin-CDKs, can compensate for Xic1 loss to promote differentiation. p27 interacts with several transcription factors either genetically or physically to govern differentiation. p27 interacts in a cyclin-CDK–independent manner with Nrf2, and binds and stabilizes Neurogenin 2 to regulate neuronal development in both frogs and mice (88–90). p27 cooperates with myogenic transcription factor, MyoD (86), to drive myogenesis (86, 87). p27 is also involved in the maintenance of muscle stem cells (MuSC). p27, together with the upstream activator AMPK, prevents apoptosis of aged MuSCs by enhancing autophagy (91). p27 also interacts functionally and genetically with transcription regulator, p130, to promote endochondral ossification (92). In keratinocyte precursors, antisense oligonucleotides to p27 disrupted the expression of differentiation markers but did not prevent growth arrest, indicating that normal keratinocyte differentiation is p27 dependent but does not require its CDK inhibitory action (93). Taken together, these findings indicate that p27 controls cell proliferation and organ size (78–80) through both cell-cycle–dependent and -independent mechanisms to regulate normal tissue progenitor expansion and differentiation. Because the p27null phenotype was not compensated by CDK2 knockout (84, 85) and some developmental defects in neurogenesis and myogenesis of p27null tissues can be compensated by expression of p27CK− (86, 88, 90), it appears that p27 has developmental actions independent of its cyclin-CDK binding. In the section below, we review emerging data that indicate a novel role for p27 in regulation of transcription. The developmental defects and organ overgrowth of p27null mice might reflect a normal role for p27 to govern gene programs that restrain tissue stem or progenitor cell self-renewal during differentiation and to integrate this with cell-cycle arrest.

Evidence for a Role for p27 as a Transcriptional Corepressor

Increasing data suggest that some of the developmental effects of p27 might result from novel actions on transcription (see Figs. 1B and 2). A limited genomic survey using chromatin immunoprecipitation (ChIP)-on-chip in quiescent MEFs showed p27 binds gene promoters as a putative corepressor with p130, E2F4, HDAC1, and SIN3A (94). Comparison of p27-annotated sites with genes differentially expressed in G0-phase wild-type (WT) MEFs versus p27null MEFs indicated that p27-target genes regulate splicing, mitochondrial function, translation, and cell cycle. Notably, interaction of p27 with p130 required the C-terminal portion of p27 and further assays support a model in which p130 recruits p27 to DNA and p27 is required to nucleate E2F4 and other corepressors (94).

It is not clear whether some transcriptional effects of p27 involve interaction with cyclin-CDKs. p27 recruitment to two putative repressed gene targets AURKA and MED18 identified by ChIP-on-chip (94), was evaluated across the cell cycle (95). At both sites, p27–promoter interaction decreased as p27 levels declined during progression from G0-phase to mid-G1-phase in synchronized NIH3T3 cells (95). ChIP-PCR also demonstrated individual recruitment of each of cyclins D2, D3, and CDK4 to the sites of p27 association, peaking in mid-G1-phase. Interactions of cyclin D2, D3, and CDK4 with these promoters decreased with p27 knockdown and were not restored by transfection of p27CK−, suggesting a need for D-type cyclin and CDK4 binding to p27 for their recruitment to chromatin. While these data raise the intriguing possibility that some transcriptional roles of p27 might involve cyclin-CDKs, further work is required to establish whether p27-dependent D-Cyclin-CDK4 recruitment reflects a tripartite complex at these promoters and whether these complexes indeed regulate target gene expression (95).

Further evidence for a role for p27 in gene repression came from MEFs and embryonic stem (ES) cells. p27−/− MEFs cells were shown to have higher basal expression of SOX2, suggesting p27 might act as SOX2 repressor. Sox2 is a critical ES cell transcription factor that maintains ES pluripotency and self-renewal (96) and drives stem cells in many different cancers (97, 98). SOX2 has an intronic regulatory element (SRR2). p27 interaction with this SOX2-SRR2 and each of p130, E2F4, and SIN3A led to SOX2 repression (99).

A genomic survey in G0-phase–arrested MEFs showed p27 is recruited to chromatin at consensus motifs of several other developmentally important transcription factors including PAX5 and MyoD, and p27 was shown to coprecipitate with each of these factors (100). p27 showed greater recruitment to distal putative intronic-binding sites compared with promoter proximal sites in G0-phase MEFs. Gene ontology analysis of protein coding p27 targets showed enrichment of pathways governing cell adhesion, differentiation, transcriptional regulation, and morphogenesis among others (100). Further work in growth arrested HCT116 colon cancer cells, showed up to half of p27-associated protein-coding gene targets were also sites of recruitment of p300/CBP-associated factor (PCAF). Correlation of ChIP-sequencing with gene expression following knockdown of each of CDKN1B and PCAF suggested that p27 acts predominantly as a PCAF corepressor to decrease target gene expression (101).

In p27null mice, p21 levels are increased and p21 appears to compensate for some cell-cycle defects of p27 loss (78–80). A recent report suggests that p27 downregulates expression of the p21 gene, CDKN1A, by repressing PITX2, a transcriptional activator of CDKN1A. Both CDKN1A and PITX2 expression were increased in p27−/− MEFs compared with WT MEFs. ChIP-PCR showed p27 recruitment to the PITX2 enhancer in association with loss of PITX2 expression and loss of p21. E2F4 was also recruited to this PITX2 site and E2F4 depletion also increased PITX2 expression supporting a model of p27-E2F4–mediated PIXT2 repression (102).

In a mouse model of K-Ras–driven pancreatic cancer, loss of p27 accelerated tumor development and decreased survival. Pancreatic acinar cells in p27−/− mice showed a disruption of apical basal polarity, premalignant acinar to ductal metaplasia, and reexpression of ductal progenitor markers, including Sox9. In the K-Ras–activated pancreatic cancer line, PANC1, WTp27 was shown to be recruited to the SOX9 promoter and to decrease its promoter activity in reported assays (103). The recruitment of corepressors was not characterized. The oncogenic cooperation between K-Ras and p27 loss was attributed in part to de-repression of SOX9 (103).

These studies, taken together, provide a body of work supporting a role for p27 in transcriptional repression of pathways governing cell adhesion, differentiation, and development. However, most of the studies above have provided little or no data to demonstrate the functional significance of p27-driven gene repression in vivo. The changes in pancreatic acinar polarity in p27−/− mice and more rapid emergence of p27−/− X-mutant K-RAS–driven pancreatic cancer were associated with, but not shown to be caused by, loss of SOX9 repression by p27 (103). In the case of SOX2 repression, p27null MEFs more readily undergo induced pluripotency due to higher endogenous levels of SOX2 expression (99). However, the functional consequences of p27-mediated transcriptional repression of SOX9, SOX2, or other gene targets in vivo in development and cancer have yet to be demonstrated.

Oncogenic Partnerships between p27pTpT and Other Transcription Factors

p27 activates STAT3 to mediate TWIST1 induction, EMT, and metastasis

In MCF12A human mammary epithelial cells, a CDK-binding defective p27pT157pT198-phosphomimetic, p27CK-DD, induced EMT, but the p27CK− allele lacking these phosphomimetic mutations did not (75). A comparison of sister breast cancer lines with low and high metastatic ability, respectively, showed the highly metastatic lines had activated PI3K and high p27pTpT (67). p27 depletion mimicked mTOR inhibition and abrogated the excess bone metastasis in the MDA-MB-231-1833 model compared with parental MDA-MB-231 (67). C-terminally phosphorylated p27 was shown to activate gene programs of EMT: in highly metastatic breast and bladder cancer lines, p27 depletion reduced expression of EMT transcription factors including TWIST1 and TGFB2, decreased activated STAT3 (pSTAT3), and reduced invasion and lung metastasis (75). In contrast, p27CK-DD transduction into low metastatic breast and bladder cancer cell lines activated pSTAT3, to upregulate TWIST1 and increase lung metastasis in vivo. Proteome analysis of 747 primary breast cancers showed p27pT157 levels correlated strongly with p27pT198, and with both pSTAT3 and PI3K activation (75). Thus, PI3K activation leads to increased p27pTpT to drive p27/STAT3 association, STAT3 activation, and STAT3-induced TWIST1, EMT, and metastasis (75). Further analysis of p27–STAT3 partnerships in transcriptional regulation is in progress.

p27 binds and transcriptionally coregulates cJun to drive programs of tumor progression

A recent study revealed a novel oncogenic cooperation between PI3K and cJun pathways: p27 phosphorylation by PI3K-activated kinases stimulates p27 association with cJun. p27 and cJun were shown to be corecruited to chromatin, leading to activation of transcription programs of cell motility and EMT to drive tumor metastasis (76). p27 thus emerges as a novel cJun coregulator, whose chromatin association is governed by C-terminal p27 phosphorylation. In cancer cells with high endogenous p27pTpT or expressing p27CK-DD, cJun was activated and interacts with p27. p27–cJun complexes colocalized to the nucleus as shown by coprecipitation in fractionated cell lysates and proximity ligations assays. Sequential ChIP-qPCR with anti-cJun and re-ChIP with anti-p27 antibodies showed both are corecruited to TGFB2 to drive its expression. Comparison of global p27 and cJun chromatin association with gene expression showed p27 and cJun are corecruited broadly to chromatin and, in highly metastatic cancer models, upregulate target genes critical for cell adhesion, cytoskeletal regulation, TGFβ pathway activation, and oncogenic signaling. The most frequent transcription factor consensus motif bound by p27 was AP1/cJun, but other developmentally important and growth regulatory transcription factor binding motifs were also observed. Evaluation of binding within 5 Kb of transcription start sites showed p27-cJun target genes were differentially regulated, either up or down in the highly metastatic versus low metastatic lines. C-terminal p27 phosphorylation increased its interaction with cJun and cJun-p27 corecruitment to chromatin.

Profiles of target genes repressed by p27-cJun suggest p27pTpT might repress differentiation pathways. Over half of cJun-binding sites were cooccupied by p27, and cJun recruitment appeared to be p27 dependent, because cJun recruitment to a majority of cooccupied chromatin sites decreased dramatically with p27 depletion. Metastasis of orthotopic mammary tumors was markedly reduced by either p27, JUN, or TGFB2 depletion in the highly metastatic lines, showing the functional importance of p27-cJun–driven gene programs to metastasis (76). Finally, human breast cancers with high p27pT157 protein showed differential expression of p27-cJun target genes compared with cancers with low p27pT157. Both high p27pT157 and upregulation of p27-cJun targets were prognostic of poor patient outcome, underlining the biologic relevance of p27/cJun-driven gene programs to disease progression (76).

Our perspective of p27 deregulation in cancers has been expanded by the discovery of the novel roles of p27 in transcription. Disruption of p27 action can occur through excess proteolysis or miRNA-mediated loss of p27 translation, but also via other mechanisms. The oncogenic effects of p27 to disrupt the cytoskeleton and to upregulate the assembly and activation of D-type cyclins are not the only or potentially even major consequences of constitutive C-terminal p27 phosphorylation in the context of PI3K activation. Up to 60% of human cancers show some level of PI3K pathway activation (104). In addition to p27-mediated effects on the actin cytoskeleton in cancers, C-terminal p27 phosphorylation in cancers would lead to profound changes in gene expression programs, disrupting adhesion and activating EMT and other oncogenic gene programs to drive metastasis. Further work is required to understand the complexity of the transcriptional machineries that interact with p27 in normal development and malignancy.

Conclusion

Our understanding of the transcriptional roles of p27 is still in its infancy. In quiescent normal MEFs, p27 appears to partner with p130, E2F4 to recruit HDAC1, and SIN3A to restrain gene expression (94, 99). In cancer models, p27 can activate both STAT3 and cJun to promote gene programs of EMT and metastasis (75, 76). Indeed, p27-cJun complexes appear to play roles to both activate and repress target genes, but mechanisms governing gene selection and induction versus repression are not yet known. p27 has been shown to interact with MyoD, NRF2, PAX5, and cJun and other developmentally important transcription factors (see Figs. 1B and 2; refs. 76, 90, 100, 102). That p27 regulates gene targets governing cell migration and EMT also supports potential transcriptional roles during development. It will be of interest to determine how the transcriptional roles of p27 might govern differentiation in different tissues and contribute to the phenotypes of p27null and p27CK− mice.

The induction of broad pro-oncogenic gene programs by constitutive PI3K-driven p27–cJun interaction on chromatin targets offers a new explanation for the profound effects of p27pTpT on tumor metastasis. It will be of interest to determine whether changes in phosphorylation across the normal cell cycle govern changes in p27′s role in transcriptional regulation and whether any of these trans-regulatory completes involve associated cyclin-CDKs.

In normal cells, AKT is transiently, periodically activated in early G1-phase and this is associated with transient accumulation and loss of p27pTpT (15). This raises the possibility that cyclic C-terminal p27 phosphorylation might regulate periodic target gene selection and contribute to G1-phase progression. Further work in normal cell types will be required to evaluate how and which periodic phosphorylation of p27 at S10 in early G1-phase, T157 and T198 shortly thereafter in mid-G1-phase, and other sites might govern interaction with different transcriptional machineries to affect target gene expression or repression. A better understanding of how p27–cJun transcriptional complexes are regulated in normal tissue development and how these go awry in cancer might identify new therapeutic targets to be exploited for tissue regeneration and illuminate other aspects of human diseases, including cancer that arise at the interface of differentiation and growth control.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was funded by DOD BCRP grant number W81XWH-17-1-0456 to J.M. Slingerland.

Footnotes

  • Cancer Res 2020;80:3451–8

  • Received November 26, 2019.
  • Revision received March 25, 2020.
  • Accepted April 21, 2020.
  • Published first April 27, 2020.

References

  1. 1.↵
    1. Chu IM,
    2. Hengst L,
    3. Slingerland JM
    . The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253–67.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Sherr CJ,
    2. Roberts JM
    . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501–12.
    OpenUrlFREE Full Text
  3. 3.↵
    1. LaBaer J,
    2. Garrett MD,
    3. Stevenson LF,
    4. Slingerland JM,
    5. Sandhu C,
    6. Chou HS,
    7. et al.
    New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847–62.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Polyak K,
    2. Kato JY,
    3. Solomon MJ,
    4. Sherr CJ,
    5. Massague J,
    6. Roberts JM,
    7. et al.
    p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9–22.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Slingerland JM,
    2. Hengst L,
    3. Pan CH,
    4. Alexander D,
    5. Stampfer MR,
    6. Reed SI
    . A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994;14:3683–94.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Koff A,
    2. Ohtsuki M,
    3. Polyak K,
    4. Roberts JM,
    5. Massague J
    . Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science 1993;260:536–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hengst L,
    2. Dulic V,
    3. Slingerland JM,
    4. Lees E,
    5. Reed SI
    . A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 1994;91:5291–5.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Reynisdottir I,
    2. Polyak K,
    3. Iavarone A,
    4. Massague J
    . Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9:1831–45.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gillies JK,
    2. Lorimer IAJ.
    Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007;6:2005–9.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Gopfert U,
    2. Kullmann M,
    3. Hengst L
    . Cell cycle-dependent translation of p27 involves a responsive element in its 5′-UTR that overlaps with a uORF. Hum Mol Genet 2003;12:1767–79.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hengst L,
    2. Reed SI.
    Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861–4.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. le Sage C,
    2. Nagel R,
    3. Agami R
    . Diverse ways to control p27(Kip1) function: miRNAs come into play. Cell Cycle 2007;6:2742–9.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Millard SS,
    2. Yan JS,
    3. Nguyen H,
    4. Pagano M,
    5. Kiyokawa H,
    6. Koff A
    . Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997;272:7093–8.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Hengst L,
    2. Gopfert U,
    3. Lashuel HA,
    4. Reed SI
    . Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dev 1998;12:3882–8.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Larrea MD,
    2. Liang J,
    3. Da ST,
    4. Hong F,
    5. Shao SH,
    6. Han K,
    7. et al.
    Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 2008;28:6462–72.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. James M,
    2. Ray A,
    3. Leznova D,
    4. Blain SW
    . Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol 2007;28:498–510.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Tsvetkov LM,
    2. Yeh KH,
    3. Lee SJ,
    4. Sun H,
    5. Zhang H
    . p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661–4.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Carrano AC,
    2. Eytan E,
    3. Hershko A,
    4. Pagano M
    . SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193–9.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Sutterluty H,
    2. Chatelain E,
    3. Marti A,
    4. Wirbelauer C,
    5. Senften M,
    6. Muller U,
    7. et al.
    p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207–14.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Chu I,
    2. Sun J,
    3. Arnaout A,
    4. Kahn H,
    5. Hanna W,
    6. Narod S,
    7. et al.
    p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007;128:281–94.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Grimmler M,
    2. Wang Y,
    3. Mund T,
    4. Cilensek Z,
    5. Keidel EM,
    6. Waddell MB,
    7. et al.
    Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007;128:269–80.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Connor MK,
    2. Kotchetkov R,
    3. Cariou S,
    4. Resch A,
    5. Lupetti R,
    6. Beniston RG,
    7. et al.
    CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003;14:201–13.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Rodier G,
    2. Montagnoli A,
    3. Di Marcotullio L,
    4. Coulombe P,
    5. Draetta GF,
    6. Pagano M,
    7. et al.
    p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001;20:6672–82.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Nakayama KI,
    2. Nakayama K
    . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369–81.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Coffer PJ,
    2. Jin J,
    3. Woodgett JR
    . Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998;335:1–13.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Toker A,
    2. Newton AC
    . Cellular signaling: pivoting around PDK-1. Cell 2000;103:185–8.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Vanhaesebroeck B,
    2. Alessi DR.
    The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000;346:561–76.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Mayer IA,
    2. Arteaga CL
    . The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 2016;67:11–28.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Scheid MP,
    2. Woodgett JR.
    PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001;2:760–8.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Liang J,
    2. Zubovitz J,
    3. Petrocelli T,
    4. Kotchetkov R,
    5. Connor MK,
    6. Han K,
    7. et al.
    PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153–60.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Shin I,
    2. Yakes FM,
    3. Rojo F,
    4. Shin NY,
    5. Bakin AV,
    6. Baselga J,
    7. et al.
    PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145–52.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Viglietto G,
    2. Motti ML,
    3. Bruni P,
    4. Melillo RM,
    5. D'Alessio A,
    6. Califano D,
    7. et al.
    Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136–44.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Hong F,
    2. Larrea MD,
    3. Doughty C,
    4. Kwiatkowski DJ,
    5. Squillace R,
    6. Slingerland JM
    . mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008;30:701–11.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Fujita N,
    2. Sato S,
    3. Katayama K,
    4. Tsuruo T
    . Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706–13.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Fujita N,
    2. Sato S,
    3. Tsuruo T
    . Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2003;278:49254–60.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Kossatz U,
    2. Vervoorts J,
    3. Nickeleit I,
    4. Sundberg HA,
    5. Arthur JSC,
    6. Manns MP,
    7. et al.
    C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J 2006;25:5159–70.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Liang J,
    2. Shao SH,
    3. Xu Z,
    4. Hennessy B,
    5. Ding Z,
    6. Larrea M,
    7. et al.
    The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218–24.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Besson A,
    2. Gurian-West M,
    3. Schmidt A,
    4. Hall A,
    5. Roberts JM
    . p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;18:862–76.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Besson A,
    2. Gurian-West M,
    3. Chen X,
    4. Kelly-Spratt KS,
    5. Kemp CJ,
    6. Roberts JM
    . A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006;20:47–64.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Nagahara H,
    2. Vocero-Akbani AM,
    3. Synder EL,
    4. Ho A,
    5. Latham DG,
    6. Lissy NA,
    7. et al.
    Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998;4:1449–52.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Larrea MD,
    2. Hong F,
    3. Wander SA,
    4. da Silva TG,
    5. Helfman D,
    6. Lannigan D,
    7. et al.
    RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A 2009;106:9268–73.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Larrea MD,
    2. Wander SA,
    3. Slingerland JM
    . p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009;8:3455–61.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Tsai LH,
    2. Gleeson JG.
    Nucleokinesis in neuronal migration. Neuron 2005;46:383–8.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Baldassarre G,
    2. Belletti B,
    3. Nicoloso MS,
    4. Schiappacassi M,
    5. Vecchione A,
    6. Spessotto P,
    7. et al.
    p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7:51–63.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Godin JD,
    2. Thomas N,
    3. Laguesse S,
    4. Malinouskaya L,
    5. Close P,
    6. Malaise O,
    7. et al.
    p27(Kip1) is a microtubule-associated protein that promotes microtubule polymerization during neuron migration. Dev Cell 2012;23:729–44.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Morelli G,
    2. Even A,
    3. Gladwyn-Ng I,
    4. Le Bail R,
    5. Shilian M,
    6. Godin JD,
    7. et al.
    p27(Kip1) modulates axonal transport by regulating alpha-tubulin acetyltransferase 1 stability. Cell Rep 2018;23:2429–42.
    OpenUrl
  47. 47.↵
    1. Besson A,
    2. Dowdy SF,
    3. Roberts JM
    . CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008;14:159–69.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Serres MP,
    2. Kossatz U,
    3. Chi Y,
    4. Roberts JM,
    5. Malek NP,
    6. Besson A
    . p27(Kip1) controls cytokinesis via the regulation of citron kinase activation. J Clin Invest 2012;122:844–58.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Wander SA,
    2. Zhao D,
    3. Slingerland JM
    . p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 2011;17:12–8.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Catzavelos C,
    2. Bhattacharya N,
    3. Ung YC,
    4. Wilson JA,
    5. Roncari L,
    6. Sandhu C,
    7. et al.
    Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227–30.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Tan P,
    2. Cady B,
    3. Wanner M,
    4. Worland P,
    5. Cukor B,
    6. Magi-Galluzzi C,
    7. et al.
    The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259–63.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Tsihlias J,
    2. Kapusta LR,
    3. DeBoer G,
    4. Morava-Protzner I,
    5. Zbieranowski I,
    6. Bhattacharya N,
    7. et al.
    Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542–8.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Porter PL,
    2. Malone KE,
    3. Heagerty PJ,
    4. Alexander GM,
    5. Gatti LA,
    6. Firpo EJ,
    7. et al.
    Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222–5.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Moller MB,
    2. Skjodt K,
    3. Mortensen LS,
    4. Pedersen NT
    . Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. Br J Haematol 1999;105:730–6.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Newman L,
    2. Xia W,
    3. Yang HY,
    4. Sahin A,
    5. Bondy M,
    6. Lukmanji F,
    7. et al.
    Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 2001;30:169–75.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. le Sage C,
    2. Nagel R,
    3. Egan DA,
    4. Schrier M,
    5. Mesman E,
    6. Mangiola A,
    7. et al.
    Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3699–708.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Galardi S,
    2. Mercatelli N,
    3. Giorda E,
    4. Massalini S,
    5. Frajese GV,
    6. Ciafre SA,
    7. et al.
    miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716–24.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Nassirpour R,
    2. Mehta PP,
    3. Baxi SM,
    4. Yin MJ
    . miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One 2013;8:e62170.
    OpenUrl
  59. 59.↵
    1. Fornari F,
    2. Gramantieri L,
    3. Ferracin M,
    4. Veronese A,
    5. Sabbioni S,
    6. Calin GA,
    7. et al.
    MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651–61.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Visone R,
    2. Russo L,
    3. Pallante P,
    4. De MI,
    5. Ferraro A,
    6. Leone V,
    7. et al.
    MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791–8.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Hou T,
    2. Ou J,
    3. Zhao X,
    4. Huang X,
    5. Huang Y,
    6. Zhang Y
    . MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer 2014;110:1260–8.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Lynch SM,
    2. McKenna MM,
    3. Walsh CP,
    4. McKenna DJ
    . miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate 2016;76:637–48.
    OpenUrl
  63. 63.↵
    1. Wang L,
    2. Wang Y,
    3. Lin J
    . MiR-152–3p promotes the development of chronic myeloid leukemia by inhibiting p27. Eur Rev Med Pharmacol Sci 2018;22:8789–96.
    OpenUrl
  64. 64.↵
    1. Lang T,
    2. Nie Y.
    MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B. Biomed Pharmacother 2016;84:1967–71.
    OpenUrl
  65. 65.↵
    1. Wang C,
    2. Ba X,
    3. Guo Y,
    4. Sun D,
    5. Jiang H,
    6. Li W,
    7. et al.
    MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma. Sci Rep 2017;7:41456.
    OpenUrl
  66. 66.↵
    1. Huang J,
    2. Zhou N,
    3. Watabe K,
    4. Lu Z,
    5. Wu F,
    6. Xu M,
    7. et al.
    Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis 2014;5:e1008.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Wander S,
    2. Zhao D,
    3. Besser A,
    4. Hong F,
    5. Wei J,
    6. Ince T,
    7. et al.
    PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat 2013;138:369–81.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Serres MP,
    2. Zlotek-Zlotkiewicz E,
    3. Concha C,
    4. Gurian-West M,
    5. Daburon V,
    6. Roberts JM,
    7. et al.
    Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene 2011:30:2846–58.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Kfir S,
    2. Ehrlich M,
    3. Goldshmid A,
    4. Liu X,
    5. Kloog Y,
    6. Henis YI
    . Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol 2005;25:8239–50.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Liu X,
    2. Sun Y,
    3. Ehrlich M,
    4. Lu T,
    5. Kloog Y,
    6. Weinberg RA,
    7. et al.
    Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 2000;19:5926–35.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Morishita D,
    2. Katayama R,
    3. Sekimizu K,
    4. Tsuruo T,
    5. Fujita N
    . Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008;68:5076–85.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Kelly-Spratt KS,
    2. Philipp-Staheli J,
    3. Gurley KE,
    4. Hoon-Kim K,
    5. Knoblaugh S,
    6. Kemp CJ
    . Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene 2009;28:3652–62.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Denicourt C,
    2. Saenz CC,
    3. Datnow B,
    4. Cui XS,
    5. Dowdy SF
    . Relocalized p27(KiP1) tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res 2007;67:9238–43.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Wu FY,
    2. Wang SE,
    3. Sanders ME,
    4. Shin I,
    5. Rojo F,
    6. Baselga J,
    7. et al.
    Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006;66:2162–72.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    1. Zhao D,
    2. Besser A,
    3. Wander S,
    4. Sun J,
    5. Wang B,
    6. Ince T,
    7. et al.
    Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene 2015;34:5447–59.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Yoon H,
    2. Kim M,
    3. Jang K,
    4. Shin M,
    5. Besser A,
    6. Xiao X,
    7. et al.
    p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proc Natl Acad Sci U S A 2019;116:7005–14.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Jochum W,
    2. Passegue E,
    3. Wagner EF
    . AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401–12.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Kiyokawa H,
    2. Kineman RD,
    3. Manova-Todorova KO,
    4. Soares VC,
    5. Hoffman ES,
    6. Ono M,
    7. et al.
    Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 1996;85:721–32.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Nakayama K,
    2. Ishida N,
    3. Shirane M,
    4. Inomata A,
    5. Inoue T,
    6. Shishido N,
    7. et al.
    Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707–20.
    OpenUrlCrossRefPubMed
  80. 80.↵
    1. Fero ML,
    2. Rivkin M,
    3. Tasch M,
    4. Porter P,
    5. Carow CE,
    6. Polyak K,
    7. et al.
    A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell 1996;85:733–44.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Fero ML,
    2. Randel E,
    3. Gurley KE,
    4. Roberts JM,
    5. Kemp CJ
    . The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177–80.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Cheng T,
    2. Rodrigues N,
    3. Dombkowski D,
    4. Stier S,
    5. Scadden DT
    . Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med 2000;6:1235–40.
    OpenUrlCrossRefPubMed
  83. 83.↵
    1. Besson A,
    2. Hwang HC,
    3. Cicero S,
    4. Donovan SL,
    5. Gurian-West M,
    6. Johnson D,
    7. et al.
    Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007;21:1731–46.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. Aleem E,
    2. Kiyokawa H,
    3. Kaldis P
    . Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005;7:831–6.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Martin A,
    2. Odajima J,
    3. Hunt SL,
    4. Dubus P,
    5. Ortega S,
    6. Malumbres M,
    7. et al.
    Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005;7:591–8.
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Vernon AE,
    2. Philpott A
    . A single cdk inhibitor, p27Xic1, functions beyond cell cycle regulation to promote muscle differentiation in Xenopus. Development 2003;130:71–83.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Messina G,
    2. Blasi C,
    3. La Rocca SA,
    4. Pompili M,
    5. Calconi A,
    6. Grossi M
    . p27Kip1 acts downstream of N-cadherin-mediated cell adhesion to promote myogenesis beyond cell cycle regulation. Mol Biol Cell 2005;16:1469–80.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    1. Vernon AE,
    2. Devine C,
    3. Philpott A
    . The cdk inhibitor p27Xic1 is required for differentiation of primary neurones in Xenopus. Development 2003;130:85–92.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Vernon AE,
    2. Movassagh M,
    3. Horan I,
    4. Wise H,
    5. Ohnuma S,
    6. Philpott A
    . Notch targets the Cdk inhibitor Xic1 to regulate differentiation but not the cell cycle in neurons. EMBO Rep 2006;7:643–8.
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Nguyen L,
    2. Besson A,
    3. Heng JI,
    4. Schuurmans C,
    5. Teboul L,
    6. Parras C,
    7. et al.
    p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 2006;20:1511–24.
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    1. White JP,
    2. Billin AN,
    3. Campbell ME,
    4. Russell AJ,
    5. Huffman KM,
    6. Kraus WE
    . The AMPK/p27(Kip1) axis regulates autophagy/apoptosis decisions in aged skeletal muscle stem cells. Stem Cell Reports 2018;11:425–39.
    OpenUrl
  92. 92.↵
    1. Yeh N,
    2. Miller JP,
    3. Gaur T,
    4. Capellini TD,
    5. Nikolich-Zugich J,
    6. de la Hoz C,
    7. et al.
    Cooperation between p27 and p107 during endochondral ossification suggests a genetic pathway controlled by p27 and p130. Mol Cell Biol 2007;27:5161–71.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Hauser PJ,
    2. Agrawal D,
    3. Flanagan M,
    4. Pledger WJ
    . The role of p27kip1 in the in vitro differentiation of murine keratinocytes. Cell Growth Differ 1997;8:203–11.
    OpenUrlAbstract
  94. 94.↵
    1. Pippa R,
    2. Espinosa L,
    3. Gundem G,
    4. Garcia-Escudero R,
    5. Dominguez A,
    6. Orlando S,
    7. et al.
    p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene 2012;31:4207–20.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Orlando S,
    2. Gallastegui E,
    3. Besson A,
    4. Abril G,
    5. Aligue R,
    6. Pujol MJ,
    7. et al.
    p27Kip1 and p21Cip1 collaborate in the regulation of transcription by recruiting cyclin-Cdk complexes on the promoters of target genes. Nucleic Acids Res 2015;43:6860–73.
    OpenUrlCrossRefPubMed
  96. 96.↵
    1. Marson A,
    2. Levine SS,
    3. Cole MF,
    4. Frampton GM,
    5. Brambrink T,
    6. Johnstone S,
    7. et al.
    Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008;134:521–33.
    OpenUrlCrossRefPubMed
  97. 97.↵
    1. Bass AJ,
    2. Watanabe H,
    3. Mermel CH,
    4. Yu S,
    5. Perner S,
    6. Verhaak RG,
    7. et al.
    SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238–42.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Leis O,
    2. Eguiara A,
    3. Lopez-Arribillaga E,
    4. Alberdi MJ,
    5. Hernandez-Garcia S,
    6. Elorriaga K,
    7. et al.
    Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2011;31:1354–65.
    OpenUrlPubMed
  99. 99.↵
    1. Li H,
    2. Collado M,
    3. Villasante A,
    4. Matheu A,
    5. Lynch CJ,
    6. Canamero M,
    7. et al.
    p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell 2012;11:845–52.
    OpenUrlCrossRefPubMed
  100. 100.↵
    1. Bicer A,
    2. Orlando S,
    3. Islam ABMM,
    4. Gallastegui E,
    5. Besson A,
    6. Aligue R,
    7. et al.
    ChIP-Seq analysis identifies p27(Kip1)-target genes involved in cell adhesion and cell signalling in mouse embryonic fibroblasts. PLoS One 2017;12:e0187891.
    OpenUrl
  101. 101.↵
    1. Perearnau A,
    2. Orlando S,
    3. Islam A,
    4. Gallastegui E,
    5. Martinez J,
    6. Jordan A,
    7. et al.
    p27Kip1, PCAF and PAX5 cooperate in the transcriptional regulation of specific target genes. Nucleic Acids Res 2017;45:5086–99.
    OpenUrl
  102. 102.↵
    1. Gallastegui E,
    2. Bicer A,
    3. Orlando S,
    4. Besson A,
    5. Pujol MJ,
    6. Bachs O
    . p27(Kip1) represses the Pitx2-mediated expression of p21(Cip1) and regulates DNA replication during cell cycle progression. Oncogene 2017;36:350–61.
    OpenUrl
  103. 103.↵
    1. Jeannot P,
    2. Callot C,
    3. Baer R,
    4. Duquesnes N,
    5. Guerra C,
    6. Guillermet-Guibert J,
    7. et al.
    Loss of p27Kip promotes metaplasia in the pancreas via the regulation of Sox9 expression. Oncotarget 2015;6:35880–92.
    OpenUrl
  104. 104.↵
    1. Wander SA,
    2. Hennessy BT,
    3. Slingerland JM
    . Next generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231–41.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
p27 as a Transcriptional Regulator: New Roles in Development and Cancer
Seyedeh Fatemeh Razavipour, Kuzhuvelil B. Harikumar and Joyce M. Slingerland
Cancer Res September 1 2020 (80) (17) 3451-3458; DOI: 10.1158/0008-5472.CAN-19-3663
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement